Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
James C. Tsai, MD, MBA, FACS, Chairman of the Department of Ophthalmology and Visual Science at the Yale Eye Center, goes over the relationship between glaucoma, ocular hypertension,…
NEW YORK (Reuters Health) – On screening colonoscopy, polyps greater than 9 mm in diameter are more likely to be detected in black individuals than in their white…
NEW YORK (Reuters Health) – The results of a new study indicate that 80% of cancer patients undergoing radiation therapy do not use medications to combat pain. Many…
NEW YORK (Reuters Health) – Even in the absence of clinical stroke, atrial fibrillation (AF) is associated with impaired cognitive function and reduced hippocampal volume, according to findings…
NEW YORK (Reuters Health) – Elective cesarean section is associated with a lower rate of mother-to-child transmission of hepatitis B virus (HBV) than is vaginal delivery, according to…
NEW YORK (Reuters Health) – With the introduction of more intensive medical therapy, revascularization for asymptomatic carotid stenosis is likely to benefit less than 5% of patients, according…
NEW YORK (Reuters Health) – While raloxifene and tamoxifen are broadly similar in reducing breast cancer risk, raloxifene appears also to lower the odds of developing endometrial cancer,…
NEW YORK (Reuters Health) – Alteplase can improve stroke outcomes even when it is not given until 3 to 4.5 hours after the stroke began, according to a…
NEW YORK (Reuters Health) – Randomized trials have shown a survival benefit to using drug-eluting stents (DES) rather than bare-metal stents (BMS) in heart disease patients. Now, the…
NEW YORK (Reuters Health) – In the treatment of lower urinary tract symptoms in men, extended-release oxybutynin plus tamsulosin is more effective than tamsulosin alone and just as…
